At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care.
EMD Serono aspires to create, improve and prolong life for people living with difficult-to-treat conditions like multiple sclerosis, cancer and infertility. Our people are courageous about advancing new science and passionate about delivering programs that make an impact on our communities.
We’re imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. Our strong pipeline explores potential new medicines across oncology, immuno-oncology and immunology, with the goal of combating a wide range of cancers, multiple sclerosis and other immunologic conditions.